Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Liquid biopsy using cell-free DNA methylation profiling offers a promising, non-invasive method for early ovarian cancer detection, recurrence monitoring, and prognosis. This advancement aids in precise diagnosis and treatment strategies for this deadly disease.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Ovarian cancer is the deadliest gynecologic malignancy.
- Late-stage diagnosis (75% of cases) leads to poor prognosis (50% 5-year survival).
- Effective diagnostic and monitoring markers are critically needed.
Purpose Of The Study
- To review advancements in molecular biology for ovarian cancer diagnosis and treatment.
- To evaluate cell-free DNA methylation analysis for ovarian cancer management.
Main Methods
- Review of randomized clinical trials on ovarian cancer.
- Examination of molecular biology and diagnostic method advancements.
- Focus on cell-free DNA methylation profiling as a liquid biopsy technique.
Main Results
- Liquid biopsy, particularly cell-free DNA methylation profiling, is an emerging non-invasive technique.
- This method shows potential for detecting tumor heterogeneity and recurrence.
- DNA methylation analysis serves as a sensitive biomarker for early screening, monitoring, and prognosis.
Conclusions
- Cell-free DNA methylation analysis presents advancements and challenges in ovarian cancer diagnosis and monitoring.
- This technique offers potential for precise diagnosis, prognosis assessment, and therapeutic response evaluation.
- The review aims to guide precise diagnosis and treatment strategies for ovarian cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
